



## General description

Rituximab is a monoclonal antibody used in treatment protocols for lymphomas and leukaemia, as well as various autoimmune inflammatory diseases.

INN	Rituximab
ATC codes	L01FA01
Medicine type	Biological agent
EML status history	<p>First added in 2015 (TRS 994) for Diffuse large B-cell lymphomas</p> <p>Added in 2015 (TRS 994) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma</p> <p>Added in 2015 (TRS 994) for Follicular lymphoma</p> <p>Added in 2023 (TRS 1049) for Multiple sclerosis</p> <p>Added in 2023 (TRS 1049) for Burkitt lymphoma including Burkitt leukaemia</p>
Wikipedia	<a href="#">Rituximab</a> 
DrugBank	<a href="#">Rituximab</a> 

## Recommendations

### Section Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

#### Indications

Diffuse large B-cell lymphomas

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

### Section Medicines for multiple sclerosis

Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

#### Indications

Multiple sclerosis

